Journal of Clinical Endocrinology & Metabolism, Vol 66, 518-525, Copyright © 1988 by Endocrine Society

ARTICLES

The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man

JM Hughes, TR Beck, CE Rose Jr and RM Carey
Department of Internal Medicine, University of Virginia Medical Center, Charlottesville 22908.

We studied the actions of iv fenoldopam, a selective dopamine-1 (DA-1) receptor agonist, in 10 normal men eating a diet containing 150 meq sodium and 60 meq potassium per day. During DA-1 receptor stimulation systemic hemodynamic function did not change. Fenoldopam resulted in an increase in urine flow rate from 13 +/- 1 (+/- SE) to a peak of 17 +/- 2 mL/min (P less than 0.05) and an increase in renal plasma flow from 344 +/- 39 to 481 +/- 44 mL/min (P less than 0.05). Urinary sodium excretion and fractional excretion of sodium both increased. Urinary sodium excretion rose to a maximum of 0.32 +/- 0.05 compared with a control value of 0.21 +/- 0.03 meq/min (P less than 0.01), while fractional excretion of sodium rose to 2.7 +/- 0.6 compared with a control value of 1.6 +/- 0.1% (P less than 0.05). The glomerular filtration rate did not change. Administration of a predominantly DA-2 antagonist during continuous DA-1 receptor stimulation did not block the fenoldopam-induced natriuresis. The rise in plasma aldosterone concentration after metoclopramide administration was blunted by DA-1 receptor activation [19.2 +/- 2.9 during control compared with 12.7 +/- 1.3 ng/dL (P less than 0.01) during fenoldopam]. No change occurred in serum potassium, plasma cortisol, or PRA. We conclude that selective DA- 1 receptor stimulation in man produces sustained natriuresis and inhibition of aldosterone release by direct renal and adrenal effects.

This article has been cited by other articles:

				J. J. Gildea, X. Wang, P. A. Jose, and R. A. Felder Differential D1 and D5 Receptor Regulation and Degradation of the Angiotensin Type 1 Receptor Hypertension, February 1, 2008; 51(2): 360 - 366. [Abstract] [Full Text] [PDF]

				M. B. Murphy, C. Murray, and G. D. Shorten Fenoldopam -- A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension N. Engl. J. Med., November 22, 2001; 345(21): 1548 - 1557. [Full Text] [PDF]

				K.-D. Wu, Y.-M. Chen, T.-S. Chu, S.-C. Chueh, M.-H. Wu, and H. Bor-Shen Expression and Localization of Human Dopamine D2 and D4 Receptor mRNA in the Adrenal Gland, Aldosterone-Producing Adenoma, and Pheochromocytoma J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4460 - 4467. [Abstract] [Full Text] [PDF]

				R. M. Carey Renal Dopamine System: Paracrine Regulator of Sodium Homeostasis and Blood Pressure Hypertension, September 1, 2001; 38(3): 297 - 302. [Abstract] [Full Text] [PDF]

				I. Yamaguchi, L. Yao, H. Sanada, R. Ozono, M. M. Mouradian, P. A. Jose, R. M. Carey, and R. A. Felder Dopamine D1A Receptors and Renin Release in Rat Juxtaglomerular Cells Hypertension, April 1, 1997; 29(4): 962 - 968. [Abstract] [Full Text]

				Z.-Q. Wang, H. M. Siragy, R. A. Felder, and R. M. Carey Intrarenal Dopamine Production and Distribution in the Rat: Physiological Control of Sodium Excretion Hypertension, January 1, 1997; 29(1): 228 - 234. [Abstract] [Full Text] [PDF]